Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM; Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Lauer MA, et al. Circulation. 2001 Dec 4;104(23):2772-7. doi: 10.1161/hc4801.100358. Circulation. 2001. PMID: 11733393 Clinical Trial.
First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study.
Kipshidze N, Iversen P, Overlie P, Dunlap T, Titus B, Lee D, Moses J, O'Hanley P, Lauer M, Leon MB. Kipshidze N, et al. Cardiovasc Revasc Med. 2007 Oct-Dec;8(4):230-5. doi: 10.1016/j.carrev.2007.04.002. Cardiovasc Revasc Med. 2007. PMID: 18053943 Clinical Trial.
19 results